N/A N=255 A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects
Obesity
Primary: Mean Percent Excess Weight Loss (%EWL) — 26.52; 9.67 percentage of EWL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 Targeted Intervention to Improve Medication Adherence in Cognitively Impaired Patients With HF (TARGET)
Heart Failure
Primary: Feasibility of AMDD to Improve Medication Adherence Via Completion Rate — 15 participants
N/A N=223 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Metastatic Breast Cancer · Advanced Breast Cancer · Metastatic Castration Resistant Prostate Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) (All Causalities) — 221; 90; 174; 24 participants
Phase 2 N=100 Evaluating Simvastatin's Potential Role in Therapy
Alzheimer Disease
Primary: Change in Cerebrospinal Fluid (CSF) Beta-amyloid-42 — -5.2; -3.1 ng/L — p=0.966
Phase 3 N=87 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
Sclerosis, Systemic
Primary: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 — -1.22; -3.92 unit on a scale — p=0.0915
Phase 3 N=65 Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar
Bipolar Disorder
Primary: Young Mania Rating Scale (YMRS) — 25.09; 30.59; 15.24; 10.22 units on a scale — p=<0.01
N/A N=24 A Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System
Menorrhagia Due to Benign Causes
Primary: Reduction in Menstrual Blood Loss to Normal Levels at 12 Months — 23 participants
Phase 2 N=54 Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
Male Breast Cancer · Stage IIIB Breast Cancer · Stage IIIC Breast Cancer
Primary: Recommended Phase II Dose as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I) — 300 mg
N/A N=60 A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System
Menorrhagia Due to Benign Causes
Primary: Reduction in Menstrual Blood Loss to Normal Levels at 12 Months — 58 participants
Phase 3 N=1,369 Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy
Chemotherapy-induced Nausea and Vomiting
Primary: No Emetic Episodes and No Rescue Medication — 71.3; 61.6 percentage of particpants — p=<0.001
Phase 3 N=532 Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
Chemotherapy-induced Nausea and Vomiting
Primary: No Emetic Episodes and No Rescue Medication — 72.7; 58.4 percentage of participants — p=<0.001
Phase 3 N=1,631 Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
Meningococcal Disease
Primary: Percentages of Subjects With hSBA Titer ≥1:4 After Receiving One, Two or Three Doses of rMenB+OMV NZ Vaccine. — 42; 47; 41; 38 percentage of Subjects
Phase 3 N=486 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis — 9.1; -48.8 percent change — p=<0.0001
Phase 2 N=10 Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Prostate Cancer
Primary: Phase 1: Maximally Tolerated Dose (MTD) of Cabazitaxel in Combination With Abiraterone Acetate — 25 mg/m^2
Phase 4 N=7 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.
Barrett's Esophagus · Esophageal Cancer
Primary: Depth of Injury — 4.0; 5.2 millimeters